GSK vs PCVX: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. GSK and PCVX share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined GSK and PCVX exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

GSK plc is a UK-headquartered global biopharma company, one of the largest by revenue, focused on preventing and treating disease through vaccines, specialty medicines, and general medicines. It reorganized in 2022 when it spun off its consumer health arm as Haleon, leaving GSK as a pure biopharma business. Its most durable franchises are vaccines, led by the shingles vaccine Shingrix and the newer RSV vaccine Arexvy, and HIV, which it manages largely through the ViiV Healthcare joint venture with a shift toward long-acting injectable regimens. It also has growing positions in respiratory, immunology and inflammation, and oncology.

Full GSK guide

Vaxcyte, Inc. (Nasdaq: PCVX) is a clinical-stage vaccine company built around a proprietary cell-free protein synthesis platform that it uses to design broad-spectrum conjugate vaccines against bacterial disease. Its lead program is VAX-31, a 31-valent pneumococcal conjugate vaccine aimed at preventing invasive pneumococcal disease in adults, which covers more serotypes than currently marketed shots from Pfizer and Merck. As of Q1 2026 the company had fully enrolled its three adult Phase 3 OPUS trials (about 6,191 adults dosed), with topline OPUS-1 data expected in Q4 2026 and OPUS-2 and OPUS-3 in the first half of 2027, plus an earlier-stage infant program and other pipeline candidates such as VAX-A1.

Full PCVX guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• GSK drivers: Vaccines franchise durability; HIV and long-acting injectables.
• PCVX drivers: VAX-31 Phase 3 readouts; Broader serotype coverage as a wedge.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The central risk is the patent cliff and pipeline dependence: maturing products face generic and biosimilar competition, and the longer-term case relies on newer launches replacing that revenue, which is never guaranteed in drug development. For PCVX, vaxcyte is pre-revenue and unprofitable, so the equity is highly sensitive to binary clinical outcomes; a weak VAX-31 Phase 3 result could sharply cut the valuation.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick GSK if you believe its drivers more; PCVX if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the GSK and PCVX guides.

GSK. These figures are approximate, tied to the asOf date, and reported in a mix of pounds and dollars because GSK is a UK company trading as a US ADR, so verify live numbers before acting. GSK's lower multiple reflects slower growth and pipeline and litigation overhangs rather than a distressed balance sheet. The stock tends to behave like a value-and-income pharma holding, so the multiple matters less than whether new launches can offset patent expiries over time.

PCVX. As a clinical-stage biotech, Vaxcyte has no product revenue and cannot be valued on earnings or standard multiples; its market cap reflects the probability-weighted value of VAX-31 and the pipeline. The roughly $2.74 billion cash balance is a large share of the market cap and funds operations through the key Phase 3 readouts. Quarterly losses in the $300 million range and periodic equity raises mean per-share dilution is an ongoing feature of the story.

Headline figures (approximate, Jul 2026): GSK shows revenue (ttm) approximately £31 to £32 billion, with vaccines, HIV, and specialty medicines the main contributors, operating margin reported around the mid-to-high 20s percent on an adjusted basis, typical of large-cap pharma, eps adjusted earnings per share reported in roughly the mid-single-digit dollars per ADR; verify the latest figure live, market cap approximately $105 to $110 billion (ADR traded around the low $50s in early 2026); PCVX shows product revenue (ttm) ~$0 (clinical-stage, no approved products), q1 2026 net loss ~$320.6M, q1 2026 r&d expense ~$312.8M, cash & investments ~$2.74B (Mar 31, 2026).

GSK and PCVX are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined GSK and PCVX exposure against your real portfolio. It is not an investment adviser.